文献速递基础与转化研究临床试验与 GCP医学人工智能与信息学

组织工程血管移植物狭窄可自发逆转

Spontaneous reversal of stenosis in tissue-engineered vascular grafts.
PubMed 文献 · Sci Transl Med · 2020-01-01

研究开发用于单心室畸形儿童的组织工程血管移植物(TEVG),在FDA批准的临床试验中作为Fontan管道植入后6个月内出现高发狭窄并成功经血管成形术治疗。基于计算模型预测狭窄可经炎症驱动、力学介导机制自发逆转,并在羊下腔静脉置换模型中验证。提示无症状早期狭窄或可安全避免血管成形术。

要点

  • TEVG作为Fontan管道植入后6个月内狭窄发生率高,但血管成形术治疗成功。
  • 计算模型预测早期狭窄可自发逆转,羊模型验证了该预测。
  • 无症状早期狭窄或可安全避免血管成形术,但需适当医学监测。

核心结论

  • TEVG早期狭窄可经炎症驱动、力学介导机制自发逆转,无症状早期狭窄或可安全避免血管成形术。

研究设计与样本

  • FDA批准的临床试验评估TEVG用于单心室畸形患者作为Fontan管道。
  • 采用数据信息计算模型进行计算机参数研究,并在羊下腔静脉置换模型中验证。

主要发现

  • 临床试验中TEVG作为Fontan管道植入后6个月内出现高发移植物狭窄,经血管成形术成功治疗。
  • 计算模拟预测早期狭窄可自发逆转,羊模型确认狭窄自发消退且通常耐受良好。
  • 模拟预测通过改变支架设计减轻早期炎症并增强合成细胞力学感知,可减轻可逆性狭窄程度。

临床怎么用

  • 无症状早期TEVG狭窄患者或可安全避免血管成形术,但仍需适当医学监测。
  • 支架设计可考虑减轻早期炎症并增强力学感知以优化下一代TEVG。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We developed a tissue-engineered vascular graft (TEVG) for use in children and present results of a U.S. Food and Drug Administration (FDA)-approved clinical trial evaluating this graft in patients with single-ventricle cardiac anomalies. The TEVG was used as a Fontan conduit to connect the inferior vena cava and pulmonary artery, but a high incidence of graft narrowing manifested within the first 6 months, which was treated successfully with angioplasty. To elucidate mechanisms underlying this early stenosis, we used a data-informed, computational model to perform in silico parametric studies of TEVG development. The simulations predicted early stenosis as observed in our clinical trial but suggested further that such narrowing could reverse spontaneously through an inflammation-driven, mechano-mediated mechanism. We tested this unexpected, model-generated hypothesis by implanting TEVGs in an ovine inferior vena cava interposition graft model, which confirmed the prediction that TEVG stenosis resolved spontaneously and was typically well tolerated. These findings have important implications for our translational research because they suggest that angioplasty may be safely avoided in patients with asymptomatic early stenosis, although there will remain a need for appropriate medical monitoring. The simulations further predicted that the degree of reversible narrowing can be mitigated by altering the scaffold design to attenuate early inflammation and increase mechano-sensing by the synthetic cells, thus suggesting a new paradigm for optimizing next-generation TEVGs. We submit that there is considerable translational advantage to combined computational-experimental studies when designing cutting-edge technologies and their clinical management.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Drews JD, Pepper VK, Best CA, et al. Spontaneous reversal of stenosis in tissue-engineered vascular grafts. Sci Transl Med. 2020. PMID: 32238576. doi:10.1126/scitranslmed.aax6919

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。